Table 2. Patient demographic data .... | American Society of Hematology

Table 2.

Patient demographic data

	Cohort 1 (N = 10) N	Cohort 2 (N = 11) N
No. patients with ER/PR+ tumors	4	4
No. patients with ER/PR− tumors	6	7
No. patients with prior radiation Rx	2	2
Mean no. prior ChemRx cycles	5	4
Phase II, CCT^* or CCB	8	11
Stage II 4-9+ nodes	1	2
Stage II 10+ nodes	4	3
Stage III, inflammatory	1^*	1^*
Stage IV, measurable	0	2
Stage IV, NED	2 (1^*)	3
Phase 1, TCM	2	0
Stage IV, measurable	2	0

	Cohort 1 (N = 10) N	Cohort 2 (N = 11) N
No. patients with ER/PR+ tumors	4	4
No. patients with ER/PR− tumors	6	7
No. patients with prior radiation Rx	2	2
Mean no. prior ChemRx cycles	5	4
Phase II, CCT^* or CCB	8	11
Stage II 4-9+ nodes	1	2
Stage II 10+ nodes	4	3
Stage III, inflammatory	1^*	1^*
Stage IV, measurable	0	2
Stage IV, NED	2 (1^*)	3
Phase 1, TCM	2	0
Stage IV, measurable	2	0

ER, estrogen receptor; PR, progesterone receptor; Rx, therapy; NED, no evidence of disease; TCM, taxotere-carboplatin.

Received CCT (cyclophosphamide-cisplatin-taxol; N = 3). Remaining phase II patients received CCB (cyclophosphamide-cisplatin-BCNU).